In conclusion, this study suggests that the disease phenotype may be altered through CALR mutant burden as well as mutant type in patients with CALR-mutated MPN, and in particular, the effect of CALR mutant burden may differ depending on the mutation type. Here, CALR is linked to myeloproliferative neoplasm.